EMIS Insights | India Pharma & Healthcare Sector Report 2022-2023

What does this sample report offer? 

India’s battle against COVID-19 took a deadly turn in 2021, with more than 420,000 lives lost in the mid-year wave of infections caused by the Delta variant. Nevertheless, there is some optimism that the worst is over for India’s pharmaceuticals and healthcare sector.


This report provides a comprehensive sector overview, with this sample providing access to:

  • Entry modes, segment opportunities and government policy
  • External and internal driving forces for the sector 
  • Medical devices net imports and pharmaceuticals net exports
  • Consumer confidence and global positioning

About EMIS Insights 

EMIS operates in and reports on countries where high reward goes hand-in-hand with high risk. We bring you time-sensitive, hard-to-get, relevant news, research and analytical data, peer comparisons and more for over 197 emerging markets. Our EMIS Insights Report suite constitutes just a proportion of our deep emerging markets information platform, which you can learn more about 
. Alternatively, explore our pay-as-you-go offerings with our EMIS Insights Industry Reports